Clinical Trial Information

Karen Teff, PhD



Principal Investigator: Karen Teff, Ph.D.


Title: The Cholinergic Anti-Inflammatory Pathway in Human Obesity and Insulin Resistance

Purpose: To determine if activation or inhibition of the nicotinic acetylcholine receptor alters levels of circulating inflammatory cytokines and insulin sensitivity in lean, obese insulin sensitive and obese insulin resistant human subjects,

Brief Description: Depending on weight and insulin resistance category, the details of the study differ. Generally, subjects must participate in two inpatient stays, each involving two days and spaced 1 month apart. Blood samples are taken hourly during the day and every 3 hours during the night for 36 hours. During this time, subjects are given either placebo, a nicotine patch, oral mecamylamine (a nicotine receptor antagonist) or a combination of two for 36 hours. At the end of this regimen, an intravenous glucose tolerance test is conducted to evaluate insulin sensitivity.

Overweight, men and women, non-smokers, no chronic diseases, no prescription medication.
Contact Info:

Name: Andrea Kyan
Phone: 267 519 4856

Click here to download study flyer

© Trustees of the University of Pennsylvania